Related Experiment Videos
Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
1Brain and Mind Centre, Central Clinical School, University of Sydney, Camperdown, NSW, 2050, Australia.
Drugs
|June 5, 2019
Summary
Small molecule inhibitors targeting leucine-rich repeat kinase 2 (LRRK2) show promise for Parkinson's disease (PD). Research highlights their potential to treat genetic and sporadic PD by reducing LRRK2 kinase activity.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Leucine-rich repeat kinase 2 (LRRK2) mutations are linked to Parkinson's disease (PD).
- Increased LRRK2 kinase activity is a key pathogenic mechanism in PD.
- Small molecule inhibitors are being developed to target LRRK2.
Purpose of the Study:
- To review the genetic and biochemical evidence linking LRRK2 mutations to PD.
- To summarize the progress in developing LRRK2 inhibitors as potential therapeutics.
- To discuss challenges and future directions for LRRK2 inhibitor translation.
Main Methods:
- Review of preclinical studies and genetic/biochemical evidence.
- Analysis of rodent and human induced pluripotent stem cell (iPSC) models.
- Evaluation of safety and efficacy data for LRRK2 inhibitors.
Main Results:
- Pathogenic LRRK2 mutations increase kinase activity, supporting inhibitor development.
- Potent and selective LRRK2 inhibitors with clinical potential have been developed.
- Preclinical models show a pathogenic role for LRRK2 kinase activity.
Conclusions:
- LRRK2 inhibitors represent a promising therapeutic strategy for Parkinson's disease.
- Further research is needed on biomarker development and clinical trial design.
- LRRK2 inhibitors may benefit both genetic and sporadic forms of PD.